Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y2K6
UPID:
UBP20_HUMAN
Alternative names:
Deubiquitinating enzyme 20; Ubiquitin thioesterase 20; Ubiquitin-specific-processing protease 20; VHL-interacting deubiquitinating enzyme 2
Alternative UPACC:
Q9Y2K6; Q541F1; Q8IXQ1; Q96LG5; Q9UQN8; Q9UQP0
Background:
Ubiquitin carboxyl-terminal hydrolase 20, also known as Deubiquitinating enzyme 20, plays a pivotal role in cellular processes such as autophagy, antiviral response, and membrane protein biogenesis. It regulates NF-kappa-B signaling, enhances cellular antiviral defenses by stabilizing STING1, and is crucial for autophagy induction by maintaining ULK1 stability. Additionally, it acts as a regulator of GPCR signaling, particularly in ADRB2 recycling and resensitization.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 20 could open doors to potential therapeutic strategies.